86 related articles for article (PubMed ID: 34110678)
1. Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019.
Mohammadi Pour P; Farzaei MH; Soleiman Dehkordi E; Bishayee A; Asgary S
Phytother Res; 2021 Oct; 35(10):5417-5426. PubMed ID: 34110678
[TBL] [Abstract][Full Text] [Related]
2. Natural Agents Modulating ACE-2: A Review of Compounds with Potential against SARS-CoV-2 Infections.
Junior AG; Tolouei SEL; Dos Reis Lívero FA; Gasparotto F; Boeing T; de Souza P
Curr Pharm Des; 2021; 27(13):1588-1596. PubMed ID: 33459225
[TBL] [Abstract][Full Text] [Related]
3. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.
Yang G; Tan Z; Zhou L; Yang M; Peng L; Liu J; Cai J; Yang R; Han J; Huang Y; He S
Hypertension; 2020 Jul; 76(1):51-58. PubMed ID: 32348166
[TBL] [Abstract][Full Text] [Related]
4. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
5. Rationalization of Mushroom-Based Preventive and Therapeutic Approaches to COVID-19: Review.
Rahman MA; Rahman MS; Bashir NMB; Mia R; Hossain A; Saha SK; Kakon AJ; Sarker NC
Int J Med Mushrooms; 2021; 23(5):1-11. PubMed ID: 34347990
[TBL] [Abstract][Full Text] [Related]
6. Natural Products: A Rich Source of Antiviral Drug Lead Candidates for the Management of COVID-19.
Wijayasinghe YS; Bhansali P; Viola RE; Kamal MA; Poddar NK
Curr Pharm Des; 2021; 27(33):3526-3550. PubMed ID: 33213322
[TBL] [Abstract][Full Text] [Related]
7. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Guo J; Huang Z; Lin L; Lv J
J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
[No Abstract] [Full Text] [Related]
8. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?
Vitiello A; Ferrara F
Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Therapeutic Potential of Natural Products.
Low Z; Lani R; Tiong V; Poh C; AbuBakar S; Hassandarvish P
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298539
[TBL] [Abstract][Full Text] [Related]
10. [ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].
Verdecchia P; Reboldi G; Cavallini C; Mazzotta G; Angeli F
G Ital Cardiol (Rome); 2020 May; 21(5):321-327. PubMed ID: 32310915
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2.
Hallaj S; Ghorbani A; Mousavi-Aghdas SA; Mirza-Aghazadeh-Attari M; Sevbitov A; Hashemi V; Hallaj T; Jadidi-Niaragh F
Immunol Cell Biol; 2021 Feb; 99(2):192-205. PubMed ID: 32864784
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
13. [COVID-19 and cardiovascular diseases].
Chazova IE; Mironova OI
Ter Arkh; 2020 Oct; 92(9):4-7. PubMed ID: 33346424
[TBL] [Abstract][Full Text] [Related]
14. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).
Lima WG; Brito JCM; da Cruz Nizer WS
Phytother Res; 2021 Feb; 35(2):743-750. PubMed ID: 32945590
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus disease 2019: a clinical review.
Yang CL; Qiu X; Zeng YK; Jiang M; Fan HR; Zhang ZM
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4585-4596. PubMed ID: 32373999
[TBL] [Abstract][Full Text] [Related]
16. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
17. CROI 2023: Acute and Post-Acute COVID-19.
Antar AAR; Peluso MJ
Top Antivir Med; 2023 May; 31(3):493-509. PubMed ID: 37315513
[TBL] [Abstract][Full Text] [Related]
18. Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19.
Thota SM; Balan V; Sivaramakrishnan V
Phytother Res; 2020 Dec; 34(12):3148-3167. PubMed ID: 32881214
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Drug Candidates for Managing the Clinical Symptoms of COVID-19: a Narrative Review.
Yun C; Lee HJ; Lee CJ
Biomol Ther (Seoul); 2021 Nov; 29(6):571-581. PubMed ID: 34615772
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: General Strategies for Herbal Therapies.
Soleymani S; Naghizadeh A; Karimi M; Zarei A; Mardi R; Kordafshari G; Esmaealzadeh N; Zargaran A
J Evid Based Integr Med; 2022; 27():2515690X211053641. PubMed ID: 34985368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
